Here, we show that in pancreatic cancer cell lines, the potent class I HDAC inhibitor entinostat synergistically enhances sensitivity to gemcitabine, and we observed this effect in both gemcitabine-sensitive and gemcitabine-resistant cell lines. This evidence concerns the gene HDAC9 and pancreatic neoplasm.